{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:24:52Z","timestamp":1790270692775,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>RTX was initially used for non-Hodgkin\u2019s lymphoma treatment and has been used in the clinical treatment of various autoimmune diseases as well as in antirejection and immune induction therapy for kidney transplant recipients. Following RTX treatment, the time for B cell regeneration varies among patients, but there is no unified recommendation for the frequency of B cell monitoring. This study aimed to investigate the clinical significance of periodic monitoring of peripheral blood B lymphocytes in individualized immunotherapy following rituximab (RTX) treatment in patients with different diseases. This study included 488 patients with different diseases divided in four groups who were hospitalized and followed up from April 2017 to March 2024 (including 77, 161, 120, and 130 cases of neuromyelitis optica, pemphigus, membranous nephropathy, and kidney transplant recipients, respectively). Dynamic changes in percentage and absolute count of peripheral blood B lymphocytes before and after RTX treatment were investigated in the four groups, as well as the number of B cell subsets in 32 patients with optic neuromyelitis after RTX treatment. Although most patients showed high expression of B cells after 24 weeks, less than 6.8% of patients still began to experience B cell regeneration within 4 weeks. Thus, regular B cell monitoring following RTX treatment is helpful to better track the remission and recurrence of the disease and provide effective laboratory support for the selection and implementation of individualized immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1513303","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:24:04Z","timestamp":1732515844000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The monitoring of B lymphocytes in non-lymphoma patients following rituximab treatment"],"prefix":"10.3389","volume":"15","author":[{"given":"Linjie","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00933-7","article-title":"Epigenetic regulation of B cells and its role in autoimmune pathogenesis","volume":"19","author":"Xiao","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting cd20 and where are we going","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in Malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12111","article-title":"Rituximab for non-hodgkin\u2019s lymphoma: A story of rapid success in translation","volume":"7","author":"Harrison","year":"2014","journal-title":"Clin Transl Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting cd20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2016.1244076","article-title":"Impact of acute kidney injury on renal allograft survival","volume":"39","author":"Nagarajan","year":"2017","journal-title":"Ren Fail"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-7445.2019.03.001","article-title":"Technical specification for clinical application of immunosuppressive agents in organ transplantation (2019 edition)","volume":"10","year":"2019","journal-title":"Organ Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116923","article-title":"Immune system-mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets","volume":"238","author":"Motavalli","year":"2019","journal-title":"Life Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.01730408","article-title":"Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.13735\/j.cjdv.1001-7089.201703128","article-title":"Mechanisms of acantholysis in pemphigus vulgaris","volume":"32","author":"Xu","year":"2018","journal-title":"Chin J Dermatovenereol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00201","article-title":"The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders","volume":"10","author":"H\u00e4usser-Kinzel","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/nxi.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0419-9","article-title":"Epigenetic programming underpins B cell dysfunction in human sle","volume":"20","author":"Scharer","year":"2019","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-2963.2021.06.002","article-title":"Diagnosis and treatment guidelines for optic neuromyelitis spectrum diseases in China (2021 edition)","volume":"28","author":"DeHui","year":"2021","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20210927-00660","article-title":"Expert consensus on the application of rituximab in the treatment of membranous nephropathy","volume":"61","author":"Minghui","year":"2022","journal-title":"Chin J Internal Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35541\/cjd.20190703","article-title":"Diagnosis and treatment of pemphigus vulgaris: an expert proposal(2020)","volume":"53","author":"Jin","year":"2020","journal-title":"Chin J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1212\/nxi.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204544","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: A randomised controlled trial","volume":"74","author":"Vital","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-7445.2019.05.012","article-title":"Technical operation specification for abo-incompatible kidney transplantation from relative living donor (2019 edition)","volume":"10","author":"Wang","year":"2019","journal-title":"Organ Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.13820\/j.cnki.gdyx.20170928.007","article-title":"Early application of low dose rituximab in abo incompatible kidney transplantation","volume":"38","author":"Jiang","year":"2017","journal-title":"Guangdong Med J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1001-1420.2022.07.007","article-title":"Abo-incompatible living donor kidney transplantation : clinical analysis of 23 cases","volume":"37","author":"Yue","year":"2022","journal-title":"J Clin Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw091","article-title":"Treatment with rituximab in idiopathic membranous nephropathy","volume":"9","author":"Fiorentino","year":"2016","journal-title":"Clin Kidney J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: A randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.032","article-title":"Pivotal role of lesional and perilesional T\/B lymphocytes in pemphigus pathogenesis","volume":"137","author":"Yuan","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jid.2019.07.717","article-title":"Autoreactive B cell differentiation in diffuse ectopic lymphoid-like structures of inflamed pemphigus lesions","volume":"140","author":"Zhou","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1212\/01.Wnl.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-4130.2023.15.001","article-title":"Consensus of experts on the application of lymphocyte subsets in hematologic Malignancies","volume":"44","year":"2023","journal-title":"Int J Lab Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20200723-00745","article-title":"Experts consensus on current management of children and adolescents with aggressive mature B-cell non-hodgkin lymphoma","volume":"58","author":"Gao","year":"2020","journal-title":"Chin J Pediatr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00540-4","article-title":"Il-17 sustains the plasma cell response via P38-mediated bcl-xl rna stability in lupus pathogenesis","volume":"18","author":"Ma","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12975","article-title":"Epigenetic gene regulation in plasma cells","volume":"303","author":"Patterson","year":"2021","journal-title":"Immunol Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1513303\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:24:12Z","timestamp":1732515852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1513303\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2024.1513303"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1513303","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"article-number":"1513303"}}